综述 |
|
|
|
|
双特异性纳米抗体的研究进展及其应用 * |
原博1,2,王杰文1,2,康广博1,2,黄鹤1,2,***() |
1 天津大学生物化学工程系 化学工程学院 天津 300350 2 天津大学 系统生物工程教育部重点实验室 天津 300072 |
|
Research Progress and Application of Bispecific Nanobody |
YUAN Bo1,2,WANG Jie-wen1,2,KANG Guang-bo1,2,HUANG He1,2,***() |
1 Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China 2 Key Laboratory of Systems Bioengineering of Ministry of Education, Tianjin University, Tianjin 300072, China |
引用本文:
原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 *[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody. China Biotechnology, 2021, 41(2/3): 78-88.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2011027
或
https://manu60.magtech.com.cn/biotech/CN/Y2021/V41/I2/3/78
|
[1] |
Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature, 1993,363(6428):446-448.
|
[2] |
Cheng X, Wang J W, Kang G B, et al. Homology modeling-based in silico affinity maturation improves the affinity of a nanobody. International Journal of Molecular Sciences, 2019,20(17):E4187.
|
[3] |
Hu M, Kang G B, Cheng X, et al. In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody. Biochemical And Biophysical Research Communications, 2020,529(4):936-942.
|
[4] |
Yang E Y, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Frontiers in Oncology, 2020,10:1182.
pmid: 32793488
|
[5] |
Wang J, Mukhtar H, Ma L, et al. VHH antibodies: reagents for mycotoxin detection in food products. Sensors(Basel Switzerland), 2018,18(2):E485.
|
[6] |
Liu Y K, Huang H. Expression of single-domain antibody in different systems. Applied Microbiology and Biotechnology, 2018,102(2):539-551.
|
[7] |
Li R W, Kang G B, Hu M, et al. Ribosome display: a potent display technology used for selecting and evolving specific binders with desired properties. Molecular Biotechnology, 2019,61(1):60-71.
|
[8] |
Peyvandi F, Scully M, Kremer Hovinga J A, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Heamostasis, 2017,15(7):1448-1452.
|
[9] |
Conrath K, Vanhollebeke B, Pays E, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006,12(5):580-584.
|
[10] |
Ren J, Zhang C, Ji F L, et al. Characterization and comparison of two peptide-tag specific nanobodies for immunoaffinity chromatography. Journal of Chromatography A, 2020,1624:461227.
|
[11] |
Kontermann R E, Brinkmann U. Bispecific antibodies. Drug Discovery Today, 2015,20(7):838-847.
doi: 10.1016/j.drudis.2015.02.008
pmid: 25728220
|
[12] |
于蕊, 陈昭烈. 新型双特异性单链抗体BiTEs及其在肿瘤治疗中的应用前景. 中国生物工程杂志, 2004,24(4):2-6.
|
|
Yu R, Chen Z L. New type bispecific single-chain antibodies BiTEs and its prospect in cancer clinical trials. China Biotechnology, 2004,24(4):2-6.
|
[13] |
Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Frontiers in Immunology, 2017,8:1603.
|
[14] |
Coppieters K, Dreier T, Silence K, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis and Rheumatism, 2006,54(6):1856-1866.
doi: 10.1002/art.21827
pmid: 16736523
|
[15] |
Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. Journal of Controlled Release, 2012,161(2):429-445.
|
[16] |
van Roy M, Ververken C, Beirnaert E, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody? ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Research & Therapy, 2015,17:135.
|
[17] |
Hmila I, Saerens D, Abderrazek R B, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. The FASEB Journal, 2010,24(9):3479-3489.
doi: 10.1096/fj.09-148213
pmid: 20410443
|
[18] |
Yang Z Y, Schmidt D, Liu W L, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. The Journal of Infectious Diseases, 2014,210(6):964-972.
pmid: 24683195
|
[19] |
Taylor P, Rossotti M A, González-Techera A, et al. Increasing the potency of neutralizing single-domain antibodies by functionalization with a CD11b/CD18 binding domain. mAbs, 2015,7(5):820-828.
pmid: 26192995
|
[20] |
Herrera C, Tremblay J M, Shoemaker C B, et al. Mechanisms of ricin toxin neutralization revealed through engineered homodimeric and heterodimeric camelid antibodies. Journal of Biological Chemistry, 2015,290(46):27880-27889.
|
[21] |
Vrentas C E, Moayeri M, Keefer A B, et al. A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection. The Journal of Biological Chemistry, 2016,291(41):21596-21606.
|
[22] |
Moayeri M, Tremblay J M, Debatis M, et al. Adenoviral expression of a bispecific VHH-based neutralizing agent that targets protective antigen provides prophylactic protection from Anthrax in mice. Clinical and Vaccine Immunology, 2016,23(3):213-218.
|
[23] |
Mars A, Bouhaouala-Zahar B, Raouafi N. Ultrasensitive sensing of Androctonus australis hector scorpion venom toxins in biological fluids using an electrochemical graphene quantum dots/nanobody-based platform. Talanta, 2018,190:182-187.
doi: 10.1016/j.talanta.2018.07.087
pmid: 30172496
|
[24] |
Sheikhi A, Hojjat-farsangi M. An immunotherapeutic method for COVID-19 patients?: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Human Vaccines & Immunotherapeutics, 2021: 17(1):92-97.
pmid: 32663051
|
[25] |
Huo J D, le Bas A, Ruza R R, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nature Structural & Molecular Biology, 2020,27(9):846-854.
|
[26] |
Cheng H W, Yang L, Cai Z Z, et al. Development of haemagglutination assay for titration of porcine circovirus type 2. Analytical Biochemistry, 2020,598:113706.
doi: 10.1016/j.ab.2020.113706
pmid: 32275892
|
[27] |
Chen Z C, Moayeri M, Purcell R. Monoclonal antibody therapies against Anthrax. Toxins, 2011,3(8):1004-1019.
|
[28] |
沈玉栋, 张咏仪, 徐振林, 等. 一种百草枯半抗原PH-A、人工抗原、抗体及其制备方法和应用:中国,CN111454171A. 2020-03-26[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111454171A&v=5W8Nfq0MU44GN8hfMungTesma9snz5lz4DdkffpZGdyLeswkG7SD58%25mmd2Fz2s5ZvTFu
|
|
Shen Y D, Zhang Y Y, Xu Z L,. et al. Paraquat hapten PH-A, artificial antigen, antibody and preparation methods and applications:Chinese, CN111454171A. 2020-03-26[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111454171A&v=5W8Nfq0MU44GN8hfMungTesma9snz5lz4DdkffpZGdyLeswkG7SD58%25mmd2Fz2s5ZvTFu
|
[29] |
Wang F, Li Z F, Yang Y Y, et al. Chemiluminescent enzyme immunoassay and bioluminescent enzyme immunoassay for tenuazonic acid mycotoxin by exploitation of nanobody and nanobody-nanoluciferase fusion. Analytical Chemistry, 2020,92(17):11935-11942.
|
[30] |
Xiang Y, Nambulli S, Xiao Z, et al. Versatile, multivalent nanobody cocktails efficiently neutralize SARS-CoV-2. bioRxiv: the preprint server for biology, 2020,370(6523):1479-1484.
|
[31] |
Raybould M I J, Kovaltsuk A, Marks C, et al. CoV-AbDab: the coronavirus antibody database. Bioinformatics, 2020, 2-3.DOI (10.1093): bioinformatics.
|
[32] |
Vosjan M J W D, Vercammen J, Kolkman J A, et al. Nanobodies targeting the hepatocyte growth factor?: potential new drugs for molecular cancer therapy. Molecular Cancer Therapeutics, 2012,11(4):1017-1025.
doi: 10.1158/1535-7163.MCT-11-0891
pmid: 22319202
|
[33] |
Ding L, Tian C P, Feng S, et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics, 2015,5(4):378-398.
|
[34] |
Alvarez-Cienfuegos A, Nu?ez-Prado N, Compte M, et al. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains. Scientific Reports, 2016,6:28643.
pmid: 27345490
|
[35] |
Shibuya Y, Haga N, Asano R, et al. Generation of camelid VHH bispecific constructs via in-cell intein-mediated protein trans-splicing. Protein Engineering Design and Selection, 2017,30(1):15-21.
|
[36] |
李洪利, 李福胜, 林兆新, 等. 一种CD3ε×CD19双特异性纳米抗体及其制备方法:中国,CN106939048A. 2017-07-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2017&filename=CN106939048A&v=sfdvmO1KUQihZoeq6wTRZHAEMhfJgkiRN%25mmd2BbhICl2wSpS4a81IRLPAlbB5Z3vBnMr.
|
|
Li H L, Li F S, Lin Z X, et al. CD3epsilon×CD19 bispecific nanometer antibody and preparation method:Chinese CN106939048A. 2017-07-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2017&filename=CN106939048A&v=sfdvmO1KUQihZoeq6wTRZHAEMhfJgkiRN%25mmd2BbhICl2wSpS4a81IRLPAlbB5Z3vBnMr.
|
[37] |
de Bruin R C G, Veluchamy J P, Lougheed S M, et al. A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. OncoImmunology, 2018,7(1):e1375641.
|
[38] |
Zhu Y N, Bassoff N, Reinshagen C, et al. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Scientific Reports, 2017,7(1):2602.
doi: 10.1038/s41598-017-02483-9
pmid: 28572590
|
[39] |
Nikkhoi S K, Rahbarizadeh F, Ranjbar S, et al. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting. Molecular Immunology, 2018,96:98-109.
|
[40] |
Li Y M, Zhou C H, Li J, et al. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS One, 2018,13(1):e0190124.
|
[41] |
de Munter S, Ingels J, Goetgeluk G, et al. Nanobody based dual specific CARs. International Journal of Molecular Sciences, 2018,19(2):403.
|
[42] |
Pan H T, Liu J Y, Deng W T, et al. Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. International Journal of Nanomedicine. 2018,13:3189-3201.
|
[43] |
Zhao Y N, Li Y M, Wu X Q, et al. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biology & Therapy, 2020,21(1):72-80.
|
[44] |
He X, Feng Z J, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood, 2020,135(10):713-723.
|
[45] |
Pedersen D V, R?sner T, Hansen A G, et al. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement. Molecular Immunology. 2020,124:200-210.
pmid: 32599335
|
[46] |
李黄金, 赵林, 温碧燕. 一种靶向EGFR二聚体界面的人源化双特异性纳米抗体: 中国,CN110894239A. 2020-03-20[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110894239A&v=DlYicxrxGrtlMNGbM2MfzB0%25mmd2F4zK80ifckpSxcPZ1kZCatCy4KK7jCJA7WXokkk5K.
|
|
Li H J, Zhao L, Wen B Y. Humanized bispecific nano antibody targeting EGFR(epidermal growth factor receptor) dimer interface:Chinese CN110894239A. 2020-03-20[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110894239A&v=DlYicxrxGrtlMNGbM2MfzB0%25mmd2F4zK80ifckpSxcPZ1kZCatCy4KK7jCJA7WXokkk5K.
|
[47] |
梁爱斌, 李萍. CAR-T细胞治疗淋巴瘤的研究进展. 临床血液学杂志, 2020,33(5):599-603.
|
|
Liang A B, Li P. Research progress of CAR-T therapy in the treatment of lymphoma. Journal of Clinical Hematology, 2020,33(5):599-603.
|
[48] |
Zajc C U, Salzer B, Taft J M, et al. Driving CARs with alternative navigation tools - the potential of engineered binding scaffolds. The FEBS Journal, 2020: feb,15523.
|
[49] |
Rahbarizadeh F, Ahmadvand D, Moghimi S M. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Advanced Drug Delivery Reviews, 2019,141:41-46.
doi: 10.1016/j.addr.2019.04.006
pmid: 31004624
|
[50] |
王振, 李静. 一种靶向CD19的新型嵌合抗原受体(CAR)及其应用: 中国,CN109721659A. 2019-05-07[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2019&filename=CN109721659A&v=mfRgSc1RPW5f%25mmd2FDkaTH2BlT%25mmd2FDCnoHiyAtjypz2a3pyibO9mCIb8r0iK6nFRwm%25mmd2F6rj.
|
|
Wang Z, Li J. Novel chimeric antigen receptor (CAR) targeting CD19 and applications:Chinese, CN109721659A. 2019-05-07[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2019&filename=CN109721659A&v=mfRgSc1RPW5f%25mmd2FDkaTH2BlT%25mmd2FDCnoHiyAtjypz2a3pyibO9mCIb8r0iK6nFRwm%25mmd2F6rj.
|
[51] |
Tseng D, Volkmer J P, Willingham S B, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America, 2013,110(27):11103-11108.
|
[52] |
Ma L L, Zhu M, Gai J W, et al. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. Journal of Nanobiotechnology, 2020,18(1):1-12.
doi: 10.1186/s12951-019-0560-5
pmid: 31898555
|
[53] |
赵振东, 张重阳, 吴维海. 一种靶向于CD22分子的嵌合抗原受体:中国,CN111518217A. 2020-08-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111518217A&v=IY2z3dn10aQ%25mmd2BsG80J5fCLlmVYMax9gRMaYOw9Gx7sw%25mmd2FN7no7RdaoLlxPYApbCUG8.
|
|
Zhao Z D, Zhang Z Y, Wu W H. The chimeric antigen receptor (CAR) targeting CD22 and applications:Chinese, CN111518217A. 2020-08-11[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN111518217A&v=IY2z3dn10aQ%25mmd2BsG80J5fCLlmVYMax9gRMaYOw9Gx7sw%25mmd2FN7no7RdaoLlxPYApbCUG8.
|
[54] |
Chen L P, Han X. Anti-PD-1 / PD-L1 therapy of human cancer: past,present,and future. The Journal of Clinical Investigation, 2015,125(9):3384-3391.
doi: 10.1172/JCI80011
pmid: 26325035
|
[55] |
Wolchok J D, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology, 2010,11(2):155-164.
doi: 10.1016/S1470-2045(09)70334-1
pmid: 20004617
|
[56] |
Reichert J M. Antibodies to watch in 2014. mAbs, 2014,6(4):799-802.
doi: 10.4161/mabs.29282
pmid: 24846335
|
[57] |
Zuazo M, Gato-Ca?as M, Llorente N, et al. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. Annals of Translational Medicine, 2017,5(19):385.
doi: 10.21037/atm.2017.06.11
pmid: 29114543
|
[58] |
Zou W P, Chen L P. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 2008,8(6):467-477.
doi: 10.1038/nri2326
pmid: 18500231
|
[59] |
万亚坤, 朱敏, 盖军伟, 等. 抗PD-L1/4-1BB双特异性抗体及其用途:中国,CN110627906A. 2019-12-31[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110627906A&v=T6F71Of58Ttb9ZgZhv0FsoWqz%25mmd2F2dk4ZZGIuFH5h0cdffN3QrOBy95aq9kpM5BNeS.
|
|
Wan Y K, Zhu M, Gai J W, et al. Anti-PD-L1/4-1BB bispecific antibody and use:Chinese, CN110627906A. 2019-12-31[2020-10-14]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SCPD&dbname=SCPD2020&filename=CN110627906A&v=T6F71Of58Ttb9ZgZhv0FsoWqz%25mmd2F2dk4ZZGIuFH5h0cdffN3QrOBy95aq9kpM5BNeS.
|
[60] |
张飞. PD-L1抗体和CTLA-4抗体介导肿瘤免疫治疗的结构生物学机制研究. 上海:上海交通大学, 2018.
|
|
Zhang F. Structural mechanisms of PD-L1 and CTLA-4 antibodies mediated tumor immunotherapy. Shanghai:Shanghai Jiaotong University, 2018.
|
[61] |
Biologics W, Co S, Biologics W, et al. New programmed death 1 binding molecule comprising at least one immunoglobulin single variable domain: China, WO2017196847-A1. 2017-11-16[2020-10-14]. http://apps.webofknowledge.com/full_record.do?colName=DIIDW&recordID=2017783473&log_event=no&search_mode=GeneralSearch&excludeEventConfig=ExcludeIfFromFullRecPage&qid=1&log_event=yes&product=UA&SID=8FwlP5CmRf2oG2FpDr2&viewType=fullRecord&doc=3&page=1.
|
[62] |
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer, 2004,4(1):11-22.
doi: 10.1038/nrc1252
pmid: 14708024
|
[63] |
Dougan M, Ingram J R, Jeong H J, et al. Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs. Cancer Immunology Research, 2018,6(4):389-401.
pmid: 29459478
|
[64] |
李可馨, 崔巍. 补体介导的肿瘤免疫逃逸及其在免疫检查点抑制剂治疗中的应用. 中华检验医学杂志, 2019,42(12):981-985.
|
|
Li K X, Cui W. Complement mediated tumor immune escape and its application in immune checkpoint inhibitors therapy. Chinese Journal of Laboratory Medicine, 2019,42(12):981-985.
|
[65] |
李翠. 纳米抗体双特异性T细胞激动剂CD3-FAP/nanoBiTE抗肿瘤效应研究. 南宁:广西医科大学, 2018.
|
|
Li C. Anti-tumor effect of nanobody-specific bispecific T cell engager CD3-FAP/NanoBiTE. Nanning:Guangxi Medical University, 2018.
|
[66] |
贾羽. HER-2双特异性纳米抗体的筛选及功能鉴定. 北京:北京化工大学, 2018.
|
|
Jia Y. Construction and functional identification of bispecific nanobody for HER-2. Beijing: Beijing University of Chemical Technology, 2018.
|
[67] |
Kaushik S B, Lebwohl M G. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. Journal of the American Academy of Dermatology, 2019,80(1):27-40.
doi: 10.1016/j.jaad.2018.06.057
pmid: 30017705
|
[68] |
van Overbeke W, Verhelle A, Everaert I, et al. Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. Molecular Therapy, 2014,22(10):1768-1778.
pmid: 25023329
|
[69] |
Steeland S, Puimège L, Vandenbroucke R E, et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. The Journal of Biological Chemistry, 2015,290(7):4022-4037.
doi: 10.1074/jbc.M114.617787
pmid: 25538244
|
[70] |
Verhelle A, Nair N, Everaert I, et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. Human Molecular Genetics, 2017,26(7):1353-1364.
doi: 10.1093/hmg/ddx056
pmid: 28334940
|
[71] |
Infirmary L G, Green L. Safety and efficacy of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F bispecific nanobody, in patients with moderate-to-severe psoriasis. Journal of the American Academy of Dermatology, 2017,76(6): AB224.
|
[72] |
Steeland S, van Ryckeghem S, Vandewalle J, et al. Simultaneous Inhibition of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 completely protects against acute inflammation and sepsis. Critical Care Medicine, 2018,46(1):E67-E75.
doi: 10.1097/CCM.0000000000002813
pmid: 29095202
|
[73] |
Strokappe N M, Hock M, Rutten L, et al. Super potent bispecific llama VHH antibodies neutralize HIV via a combination of gp41 and gp120 epitopes. Antibodies, 2019,8(2):38.
|
[74] |
Pan H C, Su Y N, Xie Y N, et al. Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artificial Cells,Nanomedicine and Biotechnology, 2020,48(1):854-866.
|
[75] |
Jossten L A, Helsen M M, van de Loo F A, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis & Rheumatism, 1996,39(5):797-809.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|